Patents by Inventor Hitesh Bhagavanbhai Mangukiya

Hitesh Bhagavanbhai Mangukiya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulation of tocilizumab and method for treating COVID-19 by inhalation
    Patent number: 11365248
    Abstract: The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: June 21, 2022
    Assignee: ANOVENT PHARMACEUTICAL (U.S.), LLC
    Inventors: Cai Gu Huang, Hitesh Bhagavanbhai Mangukiya
  • FORMULATION OF NANOANTIBODY BASED DRUGS AND A METHOD FOR TREATING THROMBOTIC THROMBOCYTOPENIC PURPURA BY INHALATION
    Publication number: 20220064328
    Abstract: The present invention relates to stable formulations of a solution of nanoantibody drug that is suitable for inhalation and a method of treating acquired thrombotic thrombocytopenic purpura by administering the drug by inhalation using a soft mist inhaler or nebulizer. The pharmaceutical formulation for inhalation comprises caplacizumab.
    Type: Application
    Filed: September 2, 2021
    Publication date: March 3, 2022
    Inventors: Cai Gu Huang, Hitesh Bhagavanbhai Mangukiya
  • FORMULATION OF TOCILIZUMAB AND METHOD FOR TREATING COVID-19 BY INHALATION
    Publication number: 20210403550
    Abstract: The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer.
    Type: Application
    Filed: June 29, 2021
    Publication date: December 30, 2021
    Inventors: Cai Gu Huang, Hitesh Bhagavanbhai Mangukiya
  • BIOPHARMACEUTICAL FORMULATION OF ANTI-PD-1, ANTI-PD-L1, AND ANTI-VEGFR THERAPEUTIC MONOCLONAL ANTIBODIES AND METHOD FOR TREATING NSCLC BY INHALATION
    Publication number: 20210403568
    Abstract: This invention relates to pharmaceutical formulations of therapeutic monoclonal antibody drugs and pharmaceutically acceptable excipients and a novel therapeutic strategy for the treatment of lung cancers including metastatic NSCLC by administration of such formulations using a soft mist inhaler and/or nebulizer. The pharmaceutical formulations comprise (a) a therapeutic monoclonal antibody selected from the group consisting of pembrolizumab, atezolizumab, nivolumab, durvalumab, and bevacizumab, (b) water, and (c) a buffer. The pharmaceutical formulations are delivered locally to the lungs by inhalation for treatment of cancer.
    Type: Application
    Filed: June 29, 2021
    Publication date: December 30, 2021
    Inventors: Cai Gu Huang, Hitesh Bhagavanbhai Mangukiya